SCHEMBL30639730

SCHEMBL30639730

COCn1c(=O)oc2ccc(B3OC(C)(C)C(C)(C)O3)cc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.40
KMO O15229 1/20 0.39
MIF P14174 7/20 0.38
CD74 P04233 5/20 0.38
ALDH1A1 P00352 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
LMNA P02545 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
TP53 P04637 1/20 0.37
MAPT P10636 1/20 0.37
CA1 P00915 1/20 0.37
CA2 P00918 1/20 0.37
CA9 Q16790 1/20 0.37
CBX7 O95931 1/20 0.37
CDYL2 Q8N8U2 1/20 0.37
CDYL Q9Y232 1/20 0.37
CDY1; CDY1B Q9Y6F8 1/20 0.37
IDO1 P14902 1/20 0.36
MEN1 O00255 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26614779 1.00 CSF1R (0.40) CSF1RKMOMIFCD74ALDH1A1
SCHEMBL298215 0.86 MAPT (0.49) KMOALDH1A1SMN1; SMN2LMNATSHR
SCHEMBL16475230 0.86 LPL (0.40) CSF1RMIFCD74ALDH1A1SMN1; SMN2
SCHEMBL30639699 0.86 LPL (0.40) CSF1RMIFCD74ALDH1A1SMN1; SMN2
SCHEMBL782308 0.84 LPL (0.41) KMOALDH1A1SMN1; SMN2LMNATSHR
SCHEMBL30639689 0.82 KMO (0.42) KMOMIFCD74ALDH1A1SMN1; SMN2
SCHEMBL30639708 0.82 MIF (0.37) CSF1RKMOMIFCD74ALDH1A1
SCHEMBL26614707 0.82 KMO (0.42) KMOMIFCD74ALDH1A1SMN1; SMN2
SCHEMBL26614727 0.82 MIF (0.37) CSF1RKMOMIFCD74ALDH1A1
SCHEMBL30639740 0.81 CA1 (0.36) CSF1RKMOMIFCD74ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4514788-A1 NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR Cerevance, Inc. (US) 2025-03-05 EP disclosed
WO-2023209368-A1 NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR Cerevance, Inc. (US) 2023-11-02 WO disclosed